Ten years' experience of surgical management of triple valve disease. Early and late results in thirty-four consecutive cases

Management of Tricuspid Valve Disease in Patients Undergoing Double Valve Replacement

The management of mild tricuspid valve disease associated with left-sided valve lesions remains controversial. Between January 1985 and September 1995, 87 patients underwent combined double (aortic and mitral) valve replacement and tricuspid valve repair at the Shanghai Chest Hospital. The early mortality was 16.1%. Predictors of early mortality were found to be New York Heart Association functional class IV and right ventricular systolic pressure of 65 mm Hg or more, by multivariable regression analysis. The mean follow-up was 4.6 years. Cumulative 3-year and 5-year survival rates in patients discharged from hospital were 80% ± 4% and 63% ± 7%. Late mortality was due to sudden death (18.7%), myocardial infarction (6.5%), and cerebral embolism or hemorrhage (31.2%). Of 48 patients still alive, 45 are in New York Heart Association functional class I or II. None of them has mild or moderate tricuspid regurgitation. Based on these results, we recommend early surgical treatment prior to the appearance of severe hemodynamic deterioration and we propose a policy of liberal indication for tricuspid annuloplasty for mild functional tricuspid insufficiency at the initial double valve replacement.

Late results after triple-valve replacement with various substitute valves

The purpose of this study was to determine what influence various combinations of mechanical and bioprosthetic valves in the aortic, mitral, and tricuspid positions had on late morbidity and mortality of 40 hospital survivors of triple-valve replacement. At operation the patients ranged in age from 27 to 69 years; 73% were women. The mean postoperative follow-up interval was 8.3 years, with a total follow-up of 331 years (100% complete). At 12 months after operation, functional class decreased from 3.3 to 1.6 (p < 0.05), cardiac index increased from 2.0 to 2.6 L.min-1 x m-2 (p < 0.05), and pulmonary artery pressures decreased from 59/27 to 40/17 mm Hg (p < 0.05). There were no differences in preoperative variables between groups. Actuarial survival for the 40 patients (exclusive of 30-day or in-hospital mortality, which was 31%) was 78% and 74% at 5 and 10 years. At the same milestones, freedom from reoperation was 96% and 54%, freedom from combined thromboembolism and anticoagulant-related hemorrhage was 68% and 56%, and freedom from all late valve-related morbidity and mortality was 64% and 25%. Comparison of the patients with two or more mechanical prostheses with the patients having two or more bioprostheses indicated no significant differences in actuarial freedom from late death, thromboembolic events, or anticoagulant-related hemorrhage. However the actuarial freedom from reoperation in the groups with two or more mechanical valves was lower than that of the groups with two or more bioprosthetic valves (0/10 versus 13/30; p < 0.05).(ABSTRACT TRUNCATED AT 250 WORDS)

Results of triple valve replacement in 91 patients: perioperative mortality and long-term follow-up

Between 1961 and 1984, 91 patients underwent simultaneous triple valve replacement at the Mayo Clinic. Of the 273 prosthetic valves used, 77% were Starr-Edwards. Perioperative (30 day) mortality was 24% to 27% between 1962 and 1974 and 7% between 1975 and 1983 (p = .17). In patients with NYHA class IV symptoms, perioperative mortality was 44%, and in those with milder symptoms, it was 8% (p less than .0001). The median follow-up was 7.5 years (range, 6 weeks to 20 years). Cumulative survival, which was calculated taking into consideration perioperative mortality, was 64% at 1 year, 55% at 5 years, 40% at 10 years, and 25% at 15 years. Multivariate analysis identified preoperative functional class and age as predictors of late survival. Among causes of late mortality were sudden death in 32.5%, congestive heart failure in 15%, thromboembolism in 12.5%, prosthetic valve dysfunction in 7.5%, and infective endocarditis in 5%. Late complications included systemic emboli in 42% (embolic rate, 12.3 events per 100 patient-years), bleeding in 22%, myocardial infarction in 16%, and infective endocarditis in 6%. Eight patients required reoperation for prosthetic valve dysfunction, and 12 patients had permanent pacemakers. Of the 29 patients still alive, 79% are in NYHA class I or II. In summary, perioperative mortality after triple valve replacement appears to be declining; long-term survival in 30 day survivors is similar to that after single valve replacement and excellent symptomatic improvement can be obtained, although morbidity is high.

Haemodynamic changes after tricuspid valve surgery. A recatheterization study in forty-five patients

Changes of the central haemodynamics at rest and during exercise were evaluated in 45 patients who underwent tricuspid valve surgery. Tricuspid valve disease was associated with left heart valvular lesions in 42 patients, while isolated tricuspid valve lesions were present in 3 patients. The pre-operative evaluation showed marked impairment of cardiac function expressed by cardiomegaly, low physical working capacity, hypokinetic central circulation, elevated right atrial pressure and pulmonary hypertension in the majority of patients. Nineteen patients underwent tricuspid valve replacement and 26 tricuspid annuloplasty. The left heart valvular lesions were corrected by prosthetic valve replacement in all patients but one, who underwent mitral commissurotomy. The Björk-Shiley tilting disc valve prosthesis was used for all valve replacements. At postoperative evaluation the patients were classified in 3 groups: (1) Group TVR- 19 patients with well-functioning tricuspid valve prostheses; (2) Group TAP - 16 patients with good functional results in tricuspid annuloplasty; and (3) Group TAP-Failure - 10 patients in whom significant tricuspid incompetence was observed. The overall response to surgery in groups TVR and TAP was about the same, leading to an increase in working capacity and cardiac output and a decrease in heart volume, right atrial pressure and pulmonary hypertension. In the TAP-failure group, this response was limited to an increase in cardiac output and mainly attributable to the corrected left heart lesions. Sustained pulmonary hypertension, failing left ventricular myocardium, residual left heart lesions and anatomical tricuspid valve changes were the likely causes of TAP-failure, which could not be predicted from the pre-operative evaluation.